Clinical factors predicting return emergency department visits in chemotherapy-induced febrile neutropenia patients

Emerging cancer therapies and granulocyte-colony stimulating factor in febrile neutropenia patients presenting to the emergency department during the COVID-19 pandemic era

“…We found the article by Heo and colleagues [ 1 ] particularly intriguing as the authors provide valuable insights into the predictive factors for return visits to the emergency department (ED) in patients with chemotherapy-induced febrile neutropenia (FN). This information can aid in the management and treatment of these patients.…”

“…The American Society of Clinical Oncology (ASCO), National Comprehensive Cancer Network (NCCN), European Society for Medical Oncology (ESMO), European Organization for Research and Treatment of Cancer (EORTC) guidelines also emphasize the importance of implementing G-CSF as a preventive measure to reduce the burden of chemotherapy-induced FN on patients, as well as to improve treatment outcomes [ [7] , [8] , [9] , [10] ]. Furthermore, it would be valuable to investigate whether the use of G-CSF could also affect the predictive factors for return visits to the ED in chemotherapy-induced FN patients, as identified in the article by Heo et al [ 1 ]. By examining the potential interplay between the use of G-CSF and these predictive factors, clinicians can optimize the management of chemotherapy-induced FN patients.…”